Multiple Sclerosis

Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile From the OCARINA II Study and Patient Preferences

Updated efficacy and safety data, and new patient-reported preference data are presented from the OCARINA II study.

Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension

This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.

Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO

MINORE is a prospective Phase IV, open-label study measuring placental transfer of ocrelizumab and potential impact on newborn B-cell levels, with detailed maternal and infant clinical outcomes, humoral immunity, safety and serum biomarkers. SOPRANINO is the first prospective study measuring pharmacodynamic and pharmacokinetic parameters of ocrelizumab in breastmilk and potential effects on infant humoral response to vaccines, safety, growth and development.

Reduced cerebrospinal fluid biomarkers (neurofilament light chain, B cells, T cells) and improved clinical/imaging assessments of disease activity are sustained after 5 years of ocrelizumab treatment: long-term extension results from OBOE

The long-term extension of this longitudinal study of ocrelizumab treatment in people with relapsing multiple sclerosis evaluated cerebrospinal fluid levels of neurofilament light chain, CD19+ B cells and CD3+ T cells up to 240 weeks.

Imaging and Fluid Biomarkers of Disability Progression During Two Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Multiple Sclerosis (MS) in CHIMES

CHIMES is a prospective, open-label, single-arm phase IV study of the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing MS. This analysis assessed imaging and blood biomarkers of disease activity over 96 weeks of treatment.

Real-world effectiveness of first-line ocrelizumab treatment in relapsing multiple sclerosis: insights from MSBase OCR-R sub-study

Real-world evidence on the effectiveness of ocrelizumab (OCR) in treatment-naïve patients, with relapsing multiple sclerosis (MS) remains limited. Here we present data from the ongoing 5-year MSBase OCR-R sub-study, in eight countries, measuring treatment persistence, disease activity, disability progression and improvement in patients with relapsing MS treated with ocrelizumab.

External site

Multiple sclerosis

Disease Education

Ocrelizumab resources

Ask a question or share feedback